GSK plc (GLAXF) stock
GLAXFOTCPharmaceutical PreparationsAlso trades as GSK
Financials through fiscal 2025, year ended Dec 31, 2025Score 9/30
$24.74+0.30 (+1.21%)
Close on Oct 19, 2026Market cap $106.83BP/E 13.3Yield –
GSK free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
For fiscal 2025 it was £6.39B, up 24.0% from the year before. Over ten years it grew 18.3% a year on average. The highest annual figure on record is £7.45B in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | £6.39B | +24.0% |
| FY2024 | Dec 31, 2024 | £5.16B | -5.5% |
| FY2023 | Dec 31, 2023 | £5.45B | -12.9% |
| FY2022 | Dec 31, 2022 | £6.26B | -10.6% |
| FY2021 | Dec 31, 2021 | £7.00B | -6.0% |
| FY2020 | Dec 31, 2020 | £7.45B | +10.3% |
| FY2019 | Dec 31, 2019 | £6.76B | -4.5% |
| FY2018 | Dec 31, 2018 | £7.08B | +31.7% |
| FY2017 | Dec 31, 2017 | £5.37B | +8.5% |
| FY2016 | Dec 31, 2016 | £4.95B | +316.7% |
| FY2015 | Dec 31, 2015 | £1.19B | – |